Followers | 241 |
Posts | 12079 |
Boards Moderated | 0 |
Alias Born | 04/05/2009 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, April 27, 2015 3:14:49 PM
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE MKT: RVP) (“RTI”) announced that on April 23, 2015, the United States District Court for the Eastern District of Texas, Marshall Division, entered an Amended Final Judgment in RTI’s suit against Becton, Dickinson and Company (“BD”) for antitrust and other claims.
The Amended Final Judgment states:
1. BD attempted to monopolize the safety syringe market.
2. BD committed false advertising under the Lanham Act.
3. RTI recovers from BD $340,524,042.00.
4. RTI recovers from BD its attorneys’ fees in the amount of $11,722,823.20.
5. RTI is further awarded post-judgment interest and costs.
6. The Court GRANTS injunctive relief consistent with its prior orders.
On April 24, 2015, BD filed a Notice of Appeal announcing its appeal of the Amended Final Judgment and various other post-trial and post judgment orders to the United States Court of Appeals for the Fifth Circuit.
RTI manufactures and markets VanishPoint® and Patient Safe® safety medical products. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. RTI’s products are distributed by various specialty and general line distributors.
For more information on RTI, visit our website at www.vanishpoint.com.
http://www.businesswire.com/news/home/20150427006168/en/Retractable-Technologies-Announces-Amended-Final-Judgment-Notice#.VT6FeIktGUk
"Someone said it takes 30 years to be an instant success" - Gabriel Barbier-Mueller, CEO of Harwood International
Recent BDX News
- New BD Research Tool Helps Scientists Study Cells that are Often Key Culprits in the Development of Cancer and Infectious Diseases • PR Newswire (US) • 06/26/2024 10:45:00 AM
- BD Announces Dates for Third Quarter and Fourth Quarter Fiscal 2024 Earnings Webcasts • PR Newswire (US) • 06/20/2024 12:30:00 PM
- Form CERT - Certification by an exchange approving securities for listing • Edgar (US Regulatory) • 06/12/2024 01:36:07 PM
- Form 8-A12B - Registration of securities [Section 12(b)] • Edgar (US Regulatory) • 06/12/2024 12:45:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 05:45:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 08:59:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 09:04:43 PM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 06/06/2024 09:06:33 PM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 06/06/2024 09:05:03 PM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 06/06/2024 09:03:40 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 06/04/2024 09:27:27 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 06/04/2024 09:26:24 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 06/04/2024 09:25:41 PM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 06/04/2024 12:26:52 PM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 06/04/2024 10:04:58 AM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 06/04/2024 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 10:33:34 AM
- BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader • PR Newswire (US) • 06/03/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 11:54:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2024 08:26:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 06:44:34 PM
- Women in U.S. Can Now Collect Their Own Sample for Cervical Cancer Screening • PR Newswire (US) • 05/15/2024 10:45:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/13/2024 08:23:48 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/10/2024 11:15:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2024 05:54:59 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM